Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2

Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines. We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class five months earlier on average. After controlling for time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups. Thus, a dichotomy exists between humoral and cellular responses elicited by the two vaccine classes. Our results have implications for the need of booster doses in vaccinated subjects and might explain the dichotomy reported between the waning protection from symptomatic infection by SARS-CoV-2 vaccination and its persisting efficacy in preventing hospitalization and death.

With the COVID-19 pandemic still raging and new SARS-CoV-2 variants, such as Delta (B.1.617.2), exhibiting increased transmissibility 1 , concerns have been raised about the efficacy of current vaccines in general as well as relative to each other. The SARS-CoV-2 vaccines that have received full approval or emergency use authorization by the US Food and Drug administration include the mRNA vaccines BNT162b2 (BioNTech-Pfizer) 2 and mRNA-1273 (Moderna) 3 , which are administered in two doses, and the single-dose, adenoviral vector vaccine Ad26.COV2.S (Johnson and Johnson-Janssen) 4 . Comparisons of protective immune responses elicited by these vaccines have focused on neutralizing titers in plasma [for example, 5,6 ]. Virus neutralization by plasma is critical to protect against viral infection, but understanding the efficacy and durability of vaccine-induced responses requires assessments of both humoral and cellular adaptive immune responses elicited by vaccination.
Here we used quantitative assays to compare antibody binding and neutralizing titers, antigenspecific B cell frequencies, and antigen-specific T cell responses in thirty-three participants with no history of SARS-CoV-2 infection, similarly divided between subjects having received mRNA vaccines (n = 16) or the adenoviral vector vaccine (n = 17). When we compared the two groups by age, gender, and co-morbidities, we found no difference in these variables except that for time elapsed since vaccination, which differed between the two groups ( Table 1). Thus, as needed, the results of the immunological assays were adjusted by the time (in days) between full vaccine administration and blood collection for the study using linear regression. All methods are described in the Supplement.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 21, 2021. ; https://doi.org/10.1101/2021.09.17.21263528 doi: medRxiv preprint Antibody binding and neutralization. All vaccines express the full-length SARS-CoV-2 Spike protein [2][3][4] . We analyzed plasma of all subjects for antibodies binding the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 Spike protein and for neutralizing antibodies.
We chose RBD as target antigen of the antibody response, because the neutralizing activity of plasma is largely directed against RBD, as shown by us and others [7][8][9] . The virus neutralization activity of plasma was measured with an assay utilizing replication-competent SARS-CoV-2 virus. We found that both Ab binding and neutralizing titers were higher in the mRNAvaccinated group relative to adenoviral vector vaccinees (Fig. 1AB). The differences between groups were statistically significant after adjusting for days since vaccination ( Table 2).
The levels of specific antibodies in the circulation physiologically decrease with time elapsed since exposure to antigen 7,10,11 . Thus, assessing durability of vaccine-induced responses and protection from occurrence and clinical severity of breakthrough infection requires the evaluation of antigen-specific B cells and T cells. To analyze the memory B cell response elicited by the vaccine, we enumerated RBD-specific B cells (RBDtetramer-positive CD19 + CD20 low ) by multi-color flow cytometry (the gating strategy is shown in Fig. S1). We found that the differences in RBD-specific B cell frequencies between the mRNAand adenoviral vector-vaccinated subjects were not statistically significant ( Fig. 1C and Table 2).
Interferon gamma (IFNγ) release assay. A straightforward method to assess antigen-specific T cells is measuring the production of T cell cytokines, such as IFNγ, by peripheral blood mononuclear cells (PBMC) stimulated ex vivo with peptides representing T cell epitopes, as performed for many infectious and non-infectious conditions (for example 12 ). We used a . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 21, 2021. ; https://doi.org/10.1101/2021.09.17.21263528 doi: medRxiv preprint previously described peptide pool containing hundreds of overlapping 15-mers derived from the Spike protein (CD4_S) 13 for PBMC stimulation and detection of IFNγ release by ELISA. This assay showed no significant differences between the two groups of vaccinees ( Fig. 1D and Table 2).
In conclusion, mRNA vaccination results in higher levels of circulating binding and neutralizing antibodies than the adenoviral vector counterpart (at least in the timeframe of our study, i.e., 5 months after vaccination on average), while the antigen-specific cellular responses to the two vaccine classes show no significant differences. Thus, a dichotomy exists between humoral and cellular immune responses elicited by the SARS-CoV-2 vaccines. One may postulate that the humoral response provides a "ready-to-go" response to reinfection that rapidly limits viral replication and the consequent development of symptoms. In contrast, memory immune responses, which require longer to be expressed even in vaccinated individuals, may best explain the persisting vaccine-induced protection against severe disease and hospitalization.
Thus, the humoral vs cellular dichotomy seen in the present study might reflect that reported between the waning protection from symptomatic infection afforded by SARS-CoV-2 vaccination and its persisting efficacy in preventing hospitalization and death [ 14 and https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3909743]. This scenario has implications for the expected effects of booster doses, which might counter the progressively increasing vulnerability to symptomatic infection by eliciting a vigorous antibody response while exerting no additional benefits on hospitalization and death rates among vaccinated, immunocompetent subjects. Future investigations will test this proposed scenario. An additional consideration is that, since vaccine-induced neutralizing antibodies are highly correlated with immune . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 21, 2021. ; protection from symptomatic infection 15,16 -a correlation supported by recent murine studies 17 , our data suggest that a booster dose of the Ad26.COV2.S is advisable, particularly in the face of the global rise of COVID-19 morbidity due to the highly infectious SARS-CoV-2 Delta variant 1 .
Indeed, the administration of a second vaccine dose of Ad26.COV2.S predictably induces a stronger antibody response than the primary vaccination, as per interim data by the manufacturer 18 .
Acknowledgements. We thank the 33 study participants that prompted this study; Dennis Burton and Pei-Yong Shi for providing biological reagents; and Martin Blaser and Karl Drlica for critical reading of the manuscript. This work was funded by NIH grants R01 HL149450, R01 HL149450-S1, U01 AI122285-S1, and UL1 TR003017, and NIH contract 75N9301900065.
Competing interests: Rutgers University has filed for patent protection for various aspects of anti-SARS-CoV-2 antibody detection and its uses. La Jolla Institute has filed for patent protection for various aspects of T cell epitope and vaccine design work. A.S. is a consultant for Gritstone, Flow Pharma, Arcturus, Immunoscape, CellCarta, Oxford Immunotec, and Avalia.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  Data are presented as mean ± standard deviation or proportion (n/N %). BMI, body mass index. *hypertension (n=6), obesity (n=3), diabetes (n=2), asthma (n=2), coronary artery disease (n=1) (some conditions were concurrent). **neutropenia (n=1), rheumatoid arthritis (n=1), use of corticosteroids (n=1).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) preprint
The copyright holder for this this version posted September 21, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) preprint
The copyright holder for this this version posted September 21, 2021.

IFNγ release assay
PBMC were washed in pre-warmed RPMI 1640 supplemented with 2 mM L-glutamine, 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin (complete RPMI) (all from Corning cellgro, Manassas, VA, USA), seeded in a 48-well cell culture plate at a density of 1 × 10 4 cells/well in complete RPMI, and stimulated with 1μg/ml of the SARS-CoV-2 MP_S peptide pool or 0.1% DMSO (vehicle control). Cell culture plates were incubated for 24 hrs at 37°C in a 5% CO2 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Statistical Analysis
Baseline demographic and other variables were tested using two-sample proportion test and Student's t-test. All flow cytometry data were analyzed with FlowJo v12 software (FlowJo LLC, Ashland, OR, USA). Measurements from all immunological assays were compared between the two study groups using the Mann-Whitney U test. Linear regression was performed to assess  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.